The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa: Hidradenitis suppurativa and adalimumab
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) has an impact on patients' quality of life. Treatment of HS is generally unsatisfactory, thus new treatments are needed. OBJECTIVES: To test the efficacy of adalimumab in HS. METHODS: This was a prospective, randomized, double-blinded, placebo-controlled, two-centre clinical trial conducted in Denmark. Inclusion criteria were age above 18 years and a clinical diagnosis of moderate to severe HS defined as Hurley stage II or III for at least 6 months. The patients were randomized 1:2 (placebo/active). Actively treated patients received adalimumab 80 mg subcutaneously (s.c.) at baseline followed by 40 mg s.c. every other week for 12 weeks. Placebo-treated patients received identical-looking injections with no active ingredient. The medicine was dispensed in sequentially numbered computer-randomized containers. Participants, care givers and those assessing the outcomes were blinded to group assignment. The primary efficacy endpoints were changes in the HS scores (Sartorius and Hurley scoring systems). Secondary efficacy endpoints included changes in pain (visual analogue scale), days with lesions and Dermatology Life Quality Index, and evaluation of scarring. Recruitment was terminated early due to expiry date of trial medication. RESULTS: Twenty-one patients were included, of whom 15 received adalimumab and six received placebo. All participants were analysed according to the intention to treat principle. A significant reduction was seen in Sartorius score after 6 weeks and an almost significant reduction was seen after 12 weeks of active treatment (-10·7 vs. 7·5, P = 0·024 and -11·3 vs. 5·8, P = 0·07) when compared with the placebo group. CONCLUSIONS: A significant reduction in HS severity was gained after 6 weeks. No long-term curative effect was uniformly seen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatigue During Head-And-Neck Radiotherapy: Prospective Study on 117 Consecutive Patients
Jereczek-Fossa, B. A., Santoro, L., Alterio, D., Franchi, B., Fiore, M. R., Fossati, P., Kowalczyk, A., Canino, P., Ansarin, M., & Orecchia, R. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.024 · Cited by 77
Cited by
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093
Self-citationJemec, G. B. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1014163 · Cited by 817
Self-citationKimball, A. B., Kerdel, F., Adams, D., Mrowietz, U., Gelfand, J. M., Gniadecki, R., Prens, E. P., Schlessinger, J., Zouboulis, C. C., van der Zee, H. H., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00004 · Cited by 428
Self-citationAlikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.067 · Cited by 400
Metadata
- Authors
- Miller, I., Lynggaard, C. D., Lophaven, S., Zachariae, C., Dufour, D. N., & Jemec, G. B. E.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-30
- Volume
- 165
- Issue
- 2
- Pages
- 391-398
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W1490634881
- Cited by
- 192
- References
- 1
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa: Hidradenitis suppurativa and adalimumab. https://app.cochat.ai/papers/10.1111/j.1365-2133.2011.10339.x
- The paper
- Miller, I., Lynggaard, C. D., Lophaven, S., Zachariae, C., Dufour, D. N., & Jemec, G. B. E. (2011). A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa: Hidradenitis suppurativa and adalimumab. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2011.10339.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.